Format

Send to

Choose Destination
See comment in PubMed Commons below
Future Neurol. 2009 Nov 1;4(6):775-784.

Development of histone deacetylase inhibitors as therapeutics for neurological disease.

Author information

  • 1Department of Molecular Biology, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA, Tel.: +1 858 784 8913.

Abstract

Postsynthetic modifications of histone and other chromosomal proteins by reversible acetylation and/or methylation regulate many aspects of chromatin dynamics, such as transcription, replication and DNA repair. Aberrant modification states are associated with several neurological and neuromotor diseases. Thus, small molecules that inhibit or activate the enzymes responsible for these chromatin modifications have received considerable attention as potential human therapeutics. This paper summarizes the current state of development of histone deacetylase inhibitors in a variety of neurological diseases.

PMID:
20177429
PMCID:
PMC2824892
DOI:
10.2217/fnl.09.55
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center